Oral Semaglutide Is Cost-Effective Compared to Most Injectable GLP-1 Drugs
Oral semaglutide was cost-effective versus 5 of 6 injectable GLP-1 receptor agonists for achieving diabetes blood sugar targets in the US market.
Quick Facts
What This Study Found
The cost-of-control analysis compared oral semaglutide 14 mg against six injectable GLP-1 receptor agonists for type 2 diabetes. The calculation divides annual drug cost by the proportion of patients reaching HbA1c targets.
For the HbA1c ≤6.5% target, costs per patient achieving control: injectable semaglutide 1 mg was cheapest at $15,430, followed by oral semaglutide 14 mg at $17,383. All others (dulaglutide, exenatide once-weekly and twice-daily, liraglutide, lixisenatide) cost more per controlled patient.
For HbA1c <7.0%: injectable semaglutide 1 mg led at $12,627, followed by oral semaglutide at $13,493. The pattern was consistent.
Oral semaglutide was likely cost-effective versus all comparators except injectable semaglutide. This matters because some patients strongly prefer pills over injections.
Key Numbers
$15,430 injectable sema; $17,383 oral sema per patient at HbA1c≤6.5%; oral sema cost-effective vs 5/6 injectables
How They Did This
Cost-of-control analysis using efficacy data from the PIONEER clinical trial program and a published network meta-analysis. Annual US treatment costs were divided by the proportion of patients achieving HbA1c targets (≤6.5% and <7.0%). This is a short-term cost-effectiveness model, not a full health economic evaluation with quality-of-life or long-term outcomes.
Why This Research Matters
Many patients with type 2 diabetes avoid injectable GLP-1 drugs despite their effectiveness. Oral semaglutide (Rybelsus) removes the injection barrier. This analysis shows the pill form is cost-effective compared to most injectables, supporting its use in patients who prefer oral medication.
The Bigger Picture
Many diabetes patients avoid injectable drugs despite their effectiveness. Oral semaglutide removes the injection barrier while maintaining comparable cost-effectiveness, potentially expanding the number of patients who benefit from GLP-1 therapy.
What This Study Doesn't Tell Us
This is a short-term model based on blood sugar targets only. It does not account for weight loss, cardiovascular benefits, or quality of life, all of which differ among GLP-1 drugs. Drug pricing varies by country and payer. The analysis uses US list prices, which may not reflect negotiated prices. No sensitivity analysis for price changes was described in the abstract.
Questions This Raises
- ?How do real-world adherence differences between oral and injectable drugs affect cost-effectiveness?
- ?Will oral semaglutide pricing change as biosimilar GLP-1 drugs enter the market?
- ?Should cost-effectiveness analyses include weight loss and cardiovascular benefits?
Trust & Context
- Key Stat:
- 5 of 6 injectable GLP-1 drugs were less cost-effective than oral semaglutide for achieving diabetes targets
- Evidence Grade:
- Moderate evidence. Based on PIONEER clinical trial data with a validated cost-of-control methodology. Limited by not including weight loss or cardiovascular outcomes.
- Study Age:
- Published in 2020. Drug pricing and clinical data have evolved since this analysis.
- Original Title:
- Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
- Published In:
- Journal of medical economics, 23(6), 650-658 (2020)
- Authors:
- Hansen, B B, Nuhoho, S, Ali, S N, Dang-Tan, T, Valentine, W J, Malkin, S J P, Hunt, B
- Database ID:
- RPEP-04840
Evidence Hierarchy
Frequently Asked Questions
Is the oral semaglutide pill as effective as the injection?
Nearly. The oral form is slightly less effective at achieving the strictest blood sugar targets, but it is effective enough to be cost-competitive with most injectable options.
Why would someone choose a pill over an injection?
Many patients are uncomfortable with needles or find daily pills more convenient than weekly injections. The oral option may help more patients start and stay on GLP-1 therapy.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04840APA
Hansen, B B; Nuhoho, S; Ali, S N; Dang-Tan, T; Valentine, W J; Malkin, S J P; Hunt, B. (2020). Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.. Journal of medical economics, 23(6), 650-658. https://doi.org/10.1080/13696998.2020.1722678
MLA
Hansen, B B, et al. "Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.." Journal of medical economics, 2020. https://doi.org/10.1080/13696998.2020.1722678
RethinkPeptides
RethinkPeptides Research Database. "Oral semaglutide versus injectable glucagon-like peptide-1 r..." RPEP-04840. Retrieved from https://rethinkpeptides.com/research/hansen-2020-oral-semaglutide-versus-injectable
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.